# DECLARATION AND POWER OF ATTORNEY FOR UNITED STATES PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name, and

I believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if more than one name is listed below) of the subject matter which is claimed and for which a United States patent is sought on the invention entitled

#### **CELL JUNCTION PDZ PROTEIN**

the specification of which:
/_/ is attached hereto.
/X / was filed on September 11, 1998 as application Serial No. 09/151,611 and if this box contains an X / /, was amended on
/_/ was filed as Patent Cooperation Treaty international application No on
I hereby state that I have reviewed and understand the contents of the above identified

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge my duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim the benefit under Title 35, United States Code, §119 or §365(a)-(b) of any foreign application(s) for patent or inventor's certificate indicated below and of any Patent Cooperation Treaty international applications(s) designating at least one country other than the United States indicated below and have also identified below any foreign application(s) for patent or inventor's certificate and Patent Cooperation Treaty international application(s) designating at least one country other than the United States for the same subject matter and having a filing date before that of the application for said subject matter the priority of which is claimed:

30543

Docket No.: PF-0599 US

Country	Number	Filing Date	Priority	Claimed
	<del>.,</del>		/ Yes	/ No
	L.	<u> </u>	/_/ Yes	/_/ No

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below.

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in said prior application(s) in the manner required by the first paragraph of Title 35, United States Code §112, I acknowledge my duty to disclose material information as defined in Title 37 Code of Federal Regulations, §1.56(a) which occurred between the filing date(s) of the prior application(s) and the national or Patent Cooperation Treaty international filing date of this application:

Application		Status (Pending,
Serial No.	Filed	Abandoned, Patented)

I hereby appoint the following:

LUCY J. BILLINGS, ESQ.	Registration No. 36,749
MICHAEL C. CERRONE, ESQ.	Registration No. 39,132
SHEELA MOHAN-PETERSON, ESQ.	Registration No. 41,201
COLETTE C. MUENZEN, ESQ.	Registration No. 39,784
LEANNE C. PRICE, ESQ.	Registration No. 42,090
KAREN J. ZELLER, ESQ.	Registration No. 37,071
LYNN E. MURRY, Patent Agent	Registration No. 42,918
DAVID G. STREETER, Patent Agent	Registration No. 43,168

respectively and individually, as my attorneys and/or agents, with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

Please address all communications to:

INCYTE PHARMACEUTICALS, INC.
PATENT DEPTARTMENT
3174 PORTER DRIVE, PALO ALTO, CA 94304

TEL: 650-855-0555 FAX: 650-845-4166

2

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Sole Inventor or First Joint Inventor:

Full name: **HENRY YUE** 

Signature: # # Lee .

Citizenship: United States of America

Residence: Sunnyvale, California

P.O. Address: 826 Lois Avenue

Sunnyvale, CA 94087

Second Joint Inventor: Full name: JANICE AU-YOUNG

Signature:

0 . 0 .

Date: Lecouler 7, 1998

Citizenship: United States of America

Residence: Berkeley, California

P.O. Address: 1419 Kains Avenue

Berkeley, California 94702

**Third Joint Inventor:** 

Full name:

CHANDRA PATTERSON

Signature:

Chaudia Patternon

Date:

12/3/98

Citizenship:

United States of America

Residence:

Mountain View, California

P.O. Address:

2189 Leland Avenue

Mountain View, CA 94040

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D. C. 2021 0 May 24, 2001.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Yue et al.

Title:

Printed:

CELL JUNCTION PDZ PROTEIN

Serial No.:

09/370,102

Filing Date:

August 6, 1999

Examiner:

Tung, P.

Group Art Unit:

1652

Commissioner for Patents Washington, D.C. 20231

### CERTIFICATE UNDER 37 C.F.R. §3.73(b), REVOCATION OF POWER OF ATTORNEY AND APPOINTMENT OF NEW ATTORNEYS

Sir:

The undersigned has reviewed all the documents in the chain of title of the aboveidentified patent application and, to the best of undersigned's knowledge and belief, title is in the assignee identified above.

Incyte Genomics, Inc., formerly known as Incyte Pharmaceuticals, Inc., having a principal place of business located at 3160 Porter Drive, Palo Alto, California 94304, certifies that it is the assignee and owner of the entire right, title and interest in, to, and under the invention described and claimed in the above-identified application by virtue of an Assignment recorded at Reel 9692, Frame 0156, hereby revokes all previous powers of attorney and appoints the following patent attorneys/agents:

Lucy J. Billings	Reg. No. 36,749
Michael C. Cerrone	Reg. No. 39,132
Diana Hamlet-Cox	Reg. No. 33,302
Richard C. Ekstrom	Reg. No. 37,027
Barrie D. Greene	Reg. No. 46,740
Matthew R. Kaser	Reg. No. 44,817

Docket No.: PF-0599-1 DIV

Lynn E. Murry	Reg. No. 42,918
Shirley A. Recipon	Reg. No. 47,016
Susan K. Sather	Reg. No. 44,316
Michelle M. Stempien	Reg. No. 41,327
David G. Streeter	Reg. No. 43,168
Stephen Todd	Reg. No. 47,139
Christopher Turner	Reg. No. 45,167
Peng Ben Wang	Reg. No. 41,420

#### Please direct all correspondence to:

Legal Department
Incyte Genomics, Inc.
3160 Porter Drive
Palo Alto, California 94304

and direct all telephone calls and facsimile transmissions to: <u>Diana Hamlet-Cox</u>, Incyte Genomics, Inc., Phone: (650) 845-4639, Fax: (650) 849-8886.

The undersigned (whose title is supplied below) is empowered to act on behalf of the assignee.

I hereby declare that all statements made herein of my own knowledge are true, and that these statements are made with the knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

INCYTE GENOMICS, INC.

Date: _	05/08/01	By: hu Shale
		Lee Bendekgey
		VP General Councel/Corporate Secretary

"Express Mail" mailing label number <u>EL 856 156 717 US</u> I hereby certify that this document and referenced attachments are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10 on the date indicated and is addressed to: Commissioner for Patents, Box Patent Application, Washington 10.9, 20231 on <u>July 18, 2001</u>.

Ву:

Printed:

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Yue et al.

Title:

**CELL JUNCTION PDZ PROTEIN** 

Serial No.:

To Be Assigned

Filing Date:

Herewith

Examiner:

To Be Assigned

Group Art Unit:

To Be Assigned

Commissioner for Patents Washington, D.C. 20231

## CERTIFICATE UNDER 37 C.F.R. §3.73(b), REVOCATION OF POWER OF ATTORNEY AND APPOINTMENT OF NEW ATTORNEYS

Sir:

The undersigned has reviewed all the documents in the chain of title of the aboveidentified patent application and, to the best of undersigned's knowledge and belief, title is in the assignee identified above.

Incyte Genomics, Inc., formerly known as Incyte Pharmaceuticals, Inc., having a principal place of business located at 3160 Porter Drive, Palo Alto, California 94304, certifies that it is the assignee and owner of the entire right, title and interest in, to, and under the invention described and claimed in the above-identified application by virtue of an Assignment recorded at Reel 9692, Frame 0156, hereby revokes all previous powers of attorney and appoints the following patent attorneys/agents:

Reg. No. 36,749
Reg. No. 39,132
Reg. No. 33,302
Reg. No. 37,027
Reg. No. 46,740
Reg. No. 44,817

81516

**Docket No.:** PF-0599-2 DIV

Lynn E. Murry	Reg. No. 42,918
Shirley A. Recipon	Reg. No. 47,016
Susan K. Sather	Reg. No. 44,316
Michelle M. Stempien	Reg. No. 41,327
David G. Streeter	Reg. No. 43,168
Stephen Todd	Reg. No. 47,139
P. Ben Wang	Reg. No. 41,420

## Please direct all correspondence to:

Legal Department
Incyte Genomics, Inc.
3160 Porter Drive
Palo Alto, California 94304

and direct all telephone calls and facsimile transmissions to: _	Diana Hamlet-Cox
Incyte Genomics, Inc., Phone: (650) 845-4639, Fax: (650) 8	49-8886.

The undersigned (whose title is supplied below) is empowered to act on behalf of the assignee.

I hereby declare that all statements made herein of my own knowledge are true, and that these statements are made with the knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

INCYTE GENOMICS, INC.

Date: July 18, 2001	By: he Shally
	Lee Bendekgey

VP, General Counsel/Corporate Secretary